AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing with Starting Material

Heidelberg, Germany, Feb. 8 (Korea Bizwire) – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility. According to a recent news release from Pfizer and BioNTech, the companies have started to develop an Omicron-based [...]